-
High-dose chemotherapy followed by autologous stem-cell transplantation versus non-myeloablative consolidation in primary CNS lymphoma (MATRix/IELSG43): a randomised phase 3 trial
Gerald Illerhaus, Andrés J.M. Ferreri, Julia Wendler, Mascha Binder, Peter Borchmann, Justin Hasenkamp, +51 more
4citations -
Switch to once-weekly, single-tablet islatravir–lenacapavir from daily standard of care for HIV-1 (ISLEND-2): a multicentre, randomised, open-label, active-controlled, phase 3 non-inferiority trial
Amy E. Colson, Princy N. Kumar, Peter Jerome Ruane, Ploenchan Chetchotisakd, Winai Ratanasuwan, Afaaf Liberty, +90 more
3citations -
Belzutifan plus lenvatinib versus cabozantinib in patients with previously treated advanced renal cell carcinoma (LITESPARK-011): an open-label, randomised, controlled, phase 3 trial
Robert John Motzer, Ray McDermott, Se Hoon Park, Mauricio Burotto, Roberto Iacovelli, Elena Verzoni, +85 more
3citations -
Standard-dose unfractionated heparin versus low-dose unfractionated heparin and low-molecular-weight heparin in extracorporeal life support (RATE): an open-label, randomised, non-inferiority trial
Olivier van Minnen, Annemieke Oude Lansink‐Hartgring, Rombout B. E. van Amstel, Bas van den Bogaard, Jeroen J. H. Bunge, Thijs Delnoij, +18 more
3citations